These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. Kovacevic KD, Greisenegger S, Langer A, Gelbenegger G, Buchtele N, Pabinger I, Petroczi K, Zhu S, Gilbert JC, Jilma B. Sci Rep; 2021 Feb 04; 11(1):3092. PubMed ID: 33542410 [Abstract] [Full Text] [Related]
5. The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer. Zhu S, Gilbert JC, Hatala P, Harvey W, Liang Z, Gao S, Kang D, Jilma B. J Thromb Haemost; 2020 May 04; 18(5):1113-1123. PubMed ID: 32011054 [Abstract] [Full Text] [Related]
6. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Mayr FB, Knöbl P, Jilma B, Siller-Matula JM, Wagner PG, Schaub RG, Gilbert JC, Jilma-Stohlawetz P. Transfusion; 2010 May 04; 50(5):1079-87. PubMed ID: 20070617 [Abstract] [Full Text] [Related]
7. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P. Thromb Haemost; 2010 Sep 04; 104(3):563-70. PubMed ID: 20589313 [Abstract] [Full Text] [Related]
8. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B. Platelets; 2009 Aug 04; 20(5):334-40. PubMed ID: 19637097 [Abstract] [Full Text] [Related]
12. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Nimjee SM, Dornbos D, Pitoc GA, Wheeler DG, Layzer JM, Venetos N, Huttinger A, Talentino SE, Musgrave NJ, Moody H, Rempel RE, Jones C, Carlisle K, Wilson J, Bratton C, Joseph ME, Khan S, Hoffman MR, Sommerville L, Becker RC, Zweier JL, Sullenger BA. Mol Ther; 2019 Jul 03; 27(7):1228-1241. PubMed ID: 30987839 [Abstract] [Full Text] [Related]
13. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. J Clin Invest; 1986 Apr 03; 77(4):1272-7. PubMed ID: 3007578 [Abstract] [Full Text] [Related]
14. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Wadanoli M, Sako D, Shaw GD, Schaub RG, Wang Q, Tchernychev B, Xu J, Porter TJ, Huang Q. Thromb Haemost; 2007 Aug 03; 98(2):397-405. PubMed ID: 17721623 [Abstract] [Full Text] [Related]
17. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy. Tauer JT, Gneuss A, Lohse JE, Jürgens T, Knöfler R. Klin Padiatr; 2011 May 03; 223(3):169-72. PubMed ID: 21509710 [Abstract] [Full Text] [Related]